Peptide-based vaccines in the treatment of specific allergy.
The efficacy of conventional allergen-specific immunotherapy (SIT) for allergic conditions and venom hypersensitivity is well documented. However it's use is limited due allergic side effects including anaphylaxis and the difficulty of standardising proteins in complex allergenic mixtures. The aim of new therapeutic strategies is to circumvent these limitations and approaches include allergen non-specific therapy, such as anti-IgE and anti-cytokine therapy and other allergen specific techniques including the peptide based vaccines (PBV), modified allergens (allergoids) and DNA vaccines. PBV are small linear peptide fragments containing T cell epitopes which are designed to reduce the ability to cross link antigen-specific IgE. Studies in animal models have confirmed proof of principle demonstrating the induction of hyporesponsiveness using high doses of peptides. However, the principle limitation to clinical use of PBV is the polymorphism of HLA class II molecules. There are ongoing clinical studies using peptide-based vaccines for cat, bee and grass allergies--looking at both immunological mechanisms and clinical outcome measures. The mechanisms underlying the efficacy of PBV appear to be similar to those described for classical immunological tolerance. Thus, the peptides may induce anergy due to absence of co-stimulation, activation-induced cell death, a switch from a Th2 to a Th1 cytokine profile, the induction of regulatory T cells or combinations of these mechanisms. Successful immunotherapy, in bee sensitive individuals, is associated with the elaboration of IL-10. Clonal deletion is unlikely as an overall mechanism as there is evidence that the subsequent in vitro response to associated, non-injected, peptides can be suppressed. Mechanistic studies continue to provide insight into the mode of action of whole allergen and peptide-based immunotherapy. Clinical studies designed on the basis of these observations hold the promise of safer vaccines with improved efficacy. Whether this strategy can be used for allergy to complex allergen mixtures such as dust mites will need further evaluation.
Alexander
Clare
C
Allergy & Clinical Immunology, Faculty of Medicine, Imperial College, Dovehouse Street, London SW3 6LY, UK.
Kay
A Barry
AB
Larché
Mark
M
D000485:Allergens / Q000276:immunology; D000818:Animals; D000937:Antigen-Antibody Reactions / Q000276:immunology; D001249:Asthma / Q000276:immunology / Q000628:therapy; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D018448:Models, Immunological; D013997:Time Factors; D022223:Vaccines, Subunit / Q000276:immunology* / Q000627:therapeutic use
D000485:Allergens; D006023:Glycoproteins; D022223:Vaccines, Subunit; C059296:Fel d 1 protein, Felis domesticus